
usd jan pm et
summari maker radiotherapi cancer system also suppli x-ray tube flat-panel digit
subsystem imag medic scientif industri applic
price-to-earnings oper ep
larg establish custom base
equip servic high switch cost
addit compani typic maintain net
cash posit gener posit free cash flow
hand industri cancer treatment
highli competit character technolog
innov new product entrant although radiat
therapi like continu integr compon
global cancer treatment protocol continu
develop drug-bas oncolog treatment
repres substanti threat compani
fiscal year end sep ep estim base cfra
oper earn histor earn report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
stk
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan stock trade
expect sep sale grow
billion oper margin declin
bp due chines tariff
manag cautious optimist
china might provid tariff relief halcyon
system also expect
see tariff mitig action carri
second half fiscal year china
second largest market expect
see increas demand china
appear commit increas access
radiat therapi
proton solut busi
revenu remain volatil seem
third parti payer consum
undecid whether margin benefit
proton beam therapi radiat therapi
outweigh consider higher cost
seem proton beam therapi
difficulti achiev high rate util
potenti due reluct insur
reimburs treatment center
struggl took
impair charg loan maryland
proton treatment center anoth
file bankruptci march
opinion hold base
valuat view catalyst
price current share price
primari market north american radiat
oncolog market larg satur
result focus increas focu
intern emerg market
expect intern order account
futur order acknowledg
potenti impact top-lin growth
remain cautiou abil
meaning expand market long
term expect particl therapi segment
remain volatil overal top-lin
growth low-to-mid-singl digit
forward earn find
risk opinion target price includ
weaker-than-expect increas machin
replac weak demand abroad
difficulti sell probeam halcyon
target price
ep estim
multipl toward high-end
five-year rang see
gain momentum china
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview varian world lead manufactur medic devic softwar
treat cancer medic condit radiotherapi stereotact radiosurgeri
stereotact bodi radiotherapi brachytherapi proton therapi var oper group two
report oper segment oncolog system varian particl therapi vpt oncolog system
repres bulk var revenu segment made total revenu
fiscal year sep respect
market profil driven age global popul improv diagnost method number
newli diagnos cancer case continu increas number new cancer case diagnos annual
project increas million million accord
intern agenc research cancer world organ
radiat therapi commonli use treatment cancer alon combin surgeri
chemotherapi common type radiotherapi use x-ray deliv extern beam
administ use linear acceler addit extern radiat radioact seed wire ribbon
sometim insert tumor bodi caviti brachytherapi modal
requir radiat pass healthi tissu
varian oncolog system busi design manufactur sell servic hardwar softwar
product treat cancer convent radiotherapi advanc treatment fix field
sbrt brachytherapi
vpt busi develop design manufactur sell servic product system deliv
proton therapi anoth form extern beam radiotherapi use proton beam treatment
cancer although proton therapi clinic use four decad wide
deploy due high capit cost var current focu improv proton therapi clinic util
reduc cost treatment per patient wide accept deploy therapi
thought especi use pediatr case larg tumor ocular tumor tumor
adjac sensit healthi tissu
major develop quarter end decemb divest former imag
compon busi varex imag corpor quarter also absorb ginzton
technolog center busi previous reflect oncolog system busi
competit landscap market radiat therapi equip softwar character
rapidly-evolv technolog intens competit price pressur view radiotherapi
radiosurgeri market primarili compet elekta ab accuray incorpor
inform imag manag simul treatment plan radiosurgeri product
compet varieti compani philip medic system raysearch laboratori ab
brainlab ag best theratron ltd
addit substanti amount resourc invest research develop new
therapi cancer success develop altern therapi cancer
immunotherapi increas efficaci new therapi exist product price decis
competitor rate market penetr competit product may render var product
obsolet noncompetit
financi trend sep revenu billion billion
divestitur var imag compon busi adjust ep vs
five-year cumul annual growth rate compound-annual-growth-rate adjust ep neg recent
year compani tend maintain net cash posit posit free cash flow defin cash
flow oper less capit expenditur
senior vice presid
senior vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral slightli posit continu
expect compani sub-industri
grow posit macro environ
compani gener benefit
laxer food drug administr fda
technolog advanc sub-industri
also mani product area
equip use non-elect procedur
howev valuat high industri
investor sentiment medic devic
compani appear shaken
volatil late think
higher valuat sub-industri
mostli warrant recent expand
margin robust revenu growth weaker
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess headwind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
although chines
govern seek lower health care cost
equip manufactur insul
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
take control hous
repres think see
significantli lower level effort
republican trump administr
tri repeal
hospit spend larg driver medic
equip sale robust
strong economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index rose vs declin
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
bid aros chines privat equiti firm cdh invest may
origin offer per share sirtex new compet bid
higher per share cdh privat equiti firm self-reportedli
billion asset manag given sirtex stock trade
per share australian market close may believ
investor serious consid cdh unsolicit acquisit bid think
develop could forc pay higher price acquir sirtex
neg /kevin huang
inc sell hold lower target
next-twelve-month ep estim near
middl five-year rang mar-q ep vs
higher estim rais fy sep ep estim
fy ep estim sale
increas constant currenc million driven
growth oncolog system segment particl therapi revenu
compani book new probeam order
quarter constant currenc basi revenu apac america
declin respect emea saw growth found
oncolog order growth weaker expect america see
growth emea apac constant currenc basi expect
acquisit sirtex close late may /kevin huang
et cfra keep hold opinion share varian medic
system rais target slightli
peer fy sep ep estim earn
benefit new tax legisl forecast effect tax rate
fy dec-q ep vs ahead
estim sale rose oncolog sale particl therapi
book two new proton order oncolog order rose
encourag var solid book oncolog believ
grow faster market averag radiat therapi jeffrey
analyst research note compani news
et cfra maintain hold opinion share varian medic
system inc rais target
ep estim multipl toward
high-end five-year rang see gain momentum
china dec-q ep vs lower estim
rais sep ep ep
dec-q sale increas constant currenc million
oncolog order dec-q million order
america increas emea apac driven acceler growth
china recent enact tariff china neg
impact revenu million oper earn million
dec-q manag cautious optimist china might provid
tariff relief halcyon system also expect see
tariff mitig action carri second half fiscal
et cfra keep hold opinion share varian medic
system inc lower target
in-lin peer ep estim multipl
near middl var five-year rang sep-q ep
vs lower estim lower fy sep
ep initi fy ep estim
sep-q sale increas constant currenc million driven
growth oncolog system segment emea region perform
strongli sep-q revenu grew year-over-year
america grew apac region grew oncolog revenu
neg impact chines retaliatori tariff enact august
implement action suppli chain commerci oper mitig
impact tariff proton beam busi
book new probeam order anoth quarter /kevin huang cfa
et cfra upgrad opinion share varian medic system
hold sell maintain twelve-month target
next-twelve-month ep estim multipl
near middl var five-year rang sell
rate base primarili valuat see compani current
trade near target price lift opinion share
hold continu expect intern order account
futur order focus much effort expand
presenc establish intern market emerg market
think compani halcyon radiotherapi machin probeam proton
therapi could long-term growth driver although remain cautiou
var abil meaning expand market addit sale
probeam histor lumpi /kevin huang cfa
system inc maintain target
line peer ep estim multipl
near middl five-year rang jun-q ep
vs higher estim lower ep
expect tariff slightli neg impact sep
jun-q sale increas constant currenc million driven
growth constant currenc oncolog system segment
particl therapi segment saw revenu compani book
new probeam order quarter tough comparison
prior-year period emea region perform well jun-q
revenu grew year-over-year constant currenc america grew
apac region saw sale declin constant currenc /kevin
system inc propos acquisit australian liver
cancer treatment compani sirtex expect close month may
schedul sirtex sharehold vote may howev compet
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
